{"log_id": 115411956091760547, "direction": 0, "words_result_num": 32, "words_result": [{"probability": {"variance": 0.013048, "average": 0.966678, "min": 0.389119}, "location": {"width": 956, "top": 159, "height": 44, "left": 131}, "words": "用时可能需要减少瑞格列杂的用药剂量。在同一究中,瑞格列奈与非贝齐和CYP3A4抑制剂伊曲康"}, {"probability": {"variance": 0.005029, "average": 0.980122, "min": 0.520377}, "location": {"width": 834, "top": 206, "height": 41, "left": 129}, "words": "合用显示出更强的降糖作用,瑞格列奈AUC增加19.4倍,半衰期从1.3小时延长到6.1小时"}, {"probability": {"variance": 0.003394, "average": 0.975811, "min": 0.782778}, "location": {"width": 272, "top": 253, "height": 31, "left": 167}, "words": "甲氧苄啶(每日两次,每次16"}, {"probability": {"variance": 0.00234, "average": 0.978877, "min": 0.736784}, "location": {"width": 587, "top": 259, "height": 37, "left": 499}, "words": "是一种弱CYP2C8抑制剂,与瑞格列奈(单剂0.25mg)同服,可"}, {"probability": {"variance": 0.006599, "average": 0.968898, "min": 0.559828}, "location": {"width": 955, "top": 299, "height": 43, "left": 128}, "words": "使瑞格列奈AUC,C1m和生物半衰期有轻微的增加(分别为1.6倍,1.4倍和1.2倍),血糖水平增加无明显"}, {"probability": {"variance": 0.019654, "average": 0.948493, "min": 0.351239}, "location": {"width": 957, "top": 345, "height": 44, "left": 124}, "words": "的统计学差异。这些缺少药效学结果的数据系根据瑞格列奈低剂量治疗获得由于尚无瑞格列奈剂量于"}, {"probability": {"variance": 0.013324, "average": 0.95218, "min": 0.448455}, "location": {"width": 963, "top": 393, "height": 42, "left": 120}, "words": "025mg与甲氧苄啶剂量高于320rug的合用安全性数据,因此应避免将瑞格列奈与甲氧苄氨嘧啶合用。如果"}, {"probability": {"variance": 0.00326, "average": 0.982924, "min": 0.698866}, "location": {"width": 579, "top": 439, "height": 37, "left": 121}, "words": "必须合用,应严密监测患者的血糖水平,并进行严密的临床监测"}, {"probability": {"variance": 0.008176, "average": 0.970209, "min": 0.502934}, "location": {"width": 918, "top": 486, "height": 42, "left": 160}, "words": "利福平足一种CYP3A4强诱导剂,也是CYP2C8诱导剂,在瑞格列奈的代谢过程中同时起诱导和抑制"}, {"probability": {"variance": 0.017134, "average": 0.929396, "min": 0.465829}, "location": {"width": 955, "top": 532, "height": 43, "left": 122}, "words": "作用。使用利福平(600mg)先明治疗7大,然后与瑞格列奈(单剂4mg)在第7大时合用,AUC降低了"}, {"probability": {"variance": 0.016904, "average": 0.9464, "min": 0.407621}, "location": {"width": 958, "top": 579, "height": 41, "left": 117}, "words": "50%(这是诱导和抑制作用的共同结果)。在最后一次服用利福平24小时后服用瑞格列奈,瑞格列的AUC"}, {"probability": {"variance": 0.001129, "average": 0.983089, "min": 0.878401}, "location": {"width": 264, "top": 626, "height": 27, "left": 116}, "words": "降低了80%单独诱导作用)"}, {"probability": {"variance": 0.002649, "average": 0.982798, "min": 0.668807}, "location": {"width": 917, "top": 671, "height": 42, "left": 155}, "words": "利福平与瑞格列奈合用可能会降低瑞格列奈的用药剂量,应严密监测患者在开始使用利福平(快速抑"}, {"probability": {"variance": 0.002698, "average": 0.980151, "min": 0.702152}, "location": {"width": 959, "top": 718, "height": 42, "left": 112}, "words": "制)增加剂量(混合抑制和诱导)和停用利福平(单独诱导)以及停用利福平约1周后,其诱导作用消失"}, {"probability": {"variance": 0.009369, "average": 0.968876, "min": 0.530602}, "location": {"width": 521, "top": 765, "height": 36, "left": 113}, "words": "时的血糖水平,并根据血糖水平调节瑞格列奈的使用剂量"}, {"probability": {"variance": 0.014245, "average": 0.946886, "min": 0.393748}, "location": {"width": 903, "top": 812, "height": 44, "left": 153}, "words": "充拉霉素是一种CYP3A4强制剂,以每日两次,每次250mg剂量与瑞格列奈(单剂0.25mg)同服"}, {"probability": {"variance": 0.018166, "average": 0.917324, "min": 0.422428}, "location": {"width": 946, "top": 859, "height": 44, "left": 109}, "words": "便瑞格列东的暴露有微弱的增加(AUC增加4倍,C增加.7倍),血清胰岛素AUC平均增加1"}, {"probability": {"variance": 0.022259, "average": 0.907437, "min": 0.529675}, "location": {"width": 196, "top": 907, "height": 26, "left": 109}, "words": "倍(Cm增加1.6倍)"}, {"probability": {"variance": 0.002512, "average": 0.983248, "min": 0.691718}, "location": {"width": 718, "top": 954, "height": 39, "left": 146}, "words": "服用瑞格列奈(单次给药4mg)的同时服用CYP3A4强抑制剂酮康唑(每口200"}, {"probability": {"variance": 0.00394, "average": 0.965834, "min": 0.814063}, "location": {"width": 141, "top": 969, "height": 25, "left": 922}, "words": "可在一定范围内"}, {"probability": {"variance": 0.012055, "average": 0.953344, "min": 0.503915}, "location": {"width": 723, "top": 1001, "height": 39, "left": 106}, "words": "增加瑞格列奈的暴露量(AUC增加1.2倍,Cmu(增加1.6倍),血糖变化低于8%"}, {"probability": {"variance": 0.016324, "average": 0.948929, "min": 0.389751}, "location": {"width": 919, "top": 1049, "height": 40, "left": 143}, "words": "瑞格列奈与西米替厂、硝苯地平或辛伐他汀合用,所有CYP3A4作用底物均显著改变瑞格列奈的药"}, {"probability": {"variance": 0.000185, "average": 0.993378, "min": 0.96297}, "location": {"width": 125, "top": 1095, "height": 26, "left": 102}, "words": "代动力学参数"}, {"probability": {"variance": 0.006671, "average": 0.974752, "min": 0.521592}, "location": {"width": 921, "top": 1142, "height": 43, "left": 140}, "words": "在健康志愿者中进行的药物相互作用研究发现,瑞格列奈对地高辛、茶碱和法华林的药代动力学特性"}, {"probability": {"variance": 0.008401, "average": 0.970576, "min": 0.530426}, "location": {"width": 599, "top": 1189, "height": 37, "left": 100}, "words": "无影响。因此在与瑞格列奈联合使用时,无需调整这些药物的剂量"}, {"probability": {"variance": 0.004684, "average": 0.976892, "min": 0.661229}, "location": {"width": 917, "top": 1237, "height": 43, "left": 139}, "words": "在健康志愿者中开展的一项药代动力学研究表明,合用口服避孕药(乙炔雌二醇/左炔诺孕)虽然会"}, {"probability": {"variance": 0.002884, "average": 0.978933, "min": 0.716746}, "location": {"width": 959, "top": 1284, "height": 45, "left": 96}, "words": "缩短瑞格列奈的达峰时间,但不会改变瑞格列奈的总生物利用度至相关临床范围。瑞格列奈对左炔诺孕酮"}, {"probability": {"variance": 0.001372, "average": 0.986209, "min": 0.782066}, "location": {"width": 769, "top": 1333, "height": 38, "left": 96}, "words": "的生物利用度没有具临床意义的影响,但不能排除对乙炔雌二醇的生物利用度的影响"}, {"probability": {"variance": 0.007935, "average": 0.963977, "min": 0.643141}, "location": {"width": 461, "top": 1381, "height": 33, "left": 139}, "words": "下列药物可能增强和或延长瑞格列奈的降血糖作用"}, {"probability": {"variance": 0.010248, "average": 0.956509, "min": 0.540937}, "location": {"width": 922, "top": 1427, "height": 42, "left": 132}, "words": "吉非贝齐,克拉霉索,酮康唑,伊曲康唑,甲氧苄啶,其他类型抗糖尿病药物,单按氧化酶抑制剂(MAO3"}, {"probability": {"variance": 0.004537, "average": 0.963918, "min": 0.74254}, "location": {"width": 934, "top": 1457, "height": 66, "left": 86}, "words": "非选择性β受体阻滞剂,血管紧张素转换酶(ACE)抑制剂,酒精以及促合成代谢的激素公司"}, {"probability": {"variance": 0.005248, "average": 0.97269, "min": 0.683061}, "location": {"width": 374, "top": 1522, "height": 34, "left": 136}, "words": "下列药物可能减弱瑞格列奈的降血糖作用"}], "language": 3}